See the DrugPatentWatch profile for apremilast

Based on the available information, the latest news about Apremilast revolves around its use in treating psoriatic arthritis and its market status.

In terms of medical research, Amgen presented new findings on Apremilast, under the brand name Otezla, at the European League Against Rheumatism (EULAR) 2023 congress [2]. The research focused on Apremilast's efficacy in treating psoriatic arthritis, particularly in patients who were intolerant or had inadequate responses to tumor necrosis factor inhibitors (TNFi). The study showed that Apremilast could provide significant improvements in joint symptoms, physical function, and quality of life for these patients [2].

As for the market status of Apremilast, the European Medicines Agency (EMA) has authorized its use for treating psoriatic arthritis and moderate to severe chronic plaque psoriasis [3]. According to DrugPatentWatch, Apremilast's patent is set to expire in 2024, which may lead to the introduction of generic versions of the drug [1].

In summary, Apremilast has shown promising results in treating psoriatic arthritis, particularly in patients who have not responded well to other treatments. Additionally, its patent expiration in 2024 may impact its market presence.

Sources:
[1] <https://www.drugpatentwatch.com/p/tradename/APREMILAST>
[2] <https://www.prnewswire.com/news-releases/amgen-presents-new-research-on-otezla-apremilast-in-psoriatic-arthritis-at-eular-2023-301837442.html>
[3] <https://www.ema.europa.eu/en/medicines/human/EPAR/apremilast-accord>